TGFBR1 and cancer: Furthermore, a few immunoinhibitors are positively correlated, while some are negatively correlated with the high-risk group in various cancer types; IL10RB, PVRL2, and TGFBR1 in most of the tumor types are increased while ADORA2A in KIRC and PAAD, and KDR and TGFBR1 in KIRC are the most significantly decreased in the high-risk group (Figure 7B).